Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Willard, Z. Brown, C. Owen, G. Dubois (Horsham, West Sussex, United Kingdom). Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists. Eur Respir J 2014; 44: Suppl. 58, 4072

Member's Comments

No comment yet.

Related content which might interest you: Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 QAW039, a slowly dissociating CRTh2 antagonist with potential for improved clinical efficacy Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Anti-inflammatory effects of the novel PDE4 inhibitor CHF6001 on virus inducible cytokines Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 ARRY-502, a potent, selective, oral CRTh2 antagonist reduces Th2 mediators in patients with mild to moderate Th2-driven asthma Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma Year: 2014 Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Preclinical evaluation of GSK2245035, a potent and selective toll-like receptor 7 (TLR7) agonist Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 LATE-BREAKING ABSTRACT: GW870086: A potent anti-inflammatory glucocorticoid with a novel pharmacological profile Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 ALX-0962, an anti-IgE Nanobody® with a dual mode of action Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Discovery of PRS-060, an inhalable CD123/IL4Ra/TH2 blocking anti-asthmatic anticalin protein re-engineered from endogenous lipocalin-1 Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015 LATE-BREAKING ABSTRACT: A novel role for CCR3 in promoting airways hyperreactivity; Role for CCR3-muscarinic M3 receptor heterodimers Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 In vitro pharmacological characterization of two novel dual-acting MABA compounds (LAS190792 and LAS191351) Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013